Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 8;20:55. doi: 10.1186/s12916-022-02248-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Reparixin inhibits NOD1/2-induced tumorigenesis of CSCC cells by inhibiting the secretion of IL-8. A IL-8 levels secreted by Siha/LV-NOD1 and Siha/LV-NOD2 cells with NOD1 and NOD2 knockdown (left panels), or ML-130 pretreatment (right panels). B IL-8 levels secreted by Siha/LV-NOD1 and Siha/LV-NOD2 treated with EVP4593 (NF-κB inhibitor). C Proliferation rates of Siha/LV-NOD1 and Siha/LV-NOD2 cells treated with Reparixin (R), EVP4593 (E), SCH772984 (S), and their combination. D, E Representative images of transwell assays showing migration and invasion of Siha/LV-NOD1 and Siha/LV-NOD2 cells treated with Reparixin or EVP4593. The percentages are shown on the right. ELISA and transwell assays were performed in triplicates and CCK8 assay in five replicates. F, G Immunoblot showing expression of ERK/p-ERK and NF-κB/p-NF-κB in the Siha/LV-NOD1 and Siha/LV-NOD2 CSCC cells (data are from three independent experiment) transfected with siRNAs. All data are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001